Spironolactone and female acne: what does the latest scientific data really say?

Why is there so much talk about spironolactone again?

For several decades, spironolactone remained a relatively niche treatment for female acne, often reserved for resistant or recurrent cases. Over the past few years, however, its use has grown strongly, supported by several good-quality clinical trials and, above all, by a major systematic review published in 2025 in JAAD Reviews.

Today, many teams regard spironolactone as a credible alternative to prolonged antibiotics in women with persistent, hormonal or recurrent acne.

Its appeal is twofold: it acts on the hormonal origin of many forms of acne while often making it possible to reduce the use of antibiotics — a major issue given the rise of bacterial resistance.

How does spironolactone work?

Spironolactone was originally an aldosterone-receptor antagonist used in cardiology and hypertension. In skin medicine, its value rests on another property: its antiandrogen effect.

It reduces the action of androgen hormones on the sebaceous glands, which progressively leads to:

• lower sebum production;
• reduced inflammation;
• fewer acne lesions forming;
• improvement of relapses in patients with hormonal sensitivity.

Unlike antibiotics, it does not directly target Cutibacterium acnes. It acts on one of the fundamental mechanisms of female acne, which explains why its effects are often more lasting after several months of treatment. To learn more about this molecule, see our full spironolactone fact-sheet.

Clinical efficacy: what do the studies really show?

One of the main contributions of the systematic review published in JAAD Reviews in 2025 is that it brought together all the randomised clinical trials and large observational studies on spironolactone in female acne.

After analysing several decades of scientific literature, the authors conclude that spironolactone is an effective treatment, particularly in women with acne that persists after adolescence.

Benefits are seen on inflammatory lesions (papules and pustules), but also on deeper nodules and chronic relapses. Several trials show that improvement generally appears between the 8th and 12th week, with continued progress up to six months of treatment.

The most recent studies also show that spironolactone often makes it possible to avoid repeated courses of antibiotics, whose prolonged use is increasingly questioned because of bacterial resistance.

The patients who respond best

The best results are seen in women with:

• acne persisting after the age of 25;
• acne on the chin and jawline;
• flare-ups before periods;
• very seborrhoeic skin;
• clinical or biological hyperandrogenism;
• polycystic ovary syndrome (PCOS);
• relapses after a course of isotretinoin.

Conversely, spironolactone is generally not the first-line treatment in adolescent males, in whom the hormonal mechanism is different.

Which dose to choose? The new recommendations

One of the most frequent questions concerns the optimal dose. For a long time, practices varied considerably from one country to another. New data now make it possible to propose much more consistent recommendations.

Most specialists now start treatment at 50 mg per day, then gradually increase to 100 mg per day after two to four weeks if tolerability is satisfactory.

The JAAD Reviews review shows that 100 mg per day represents the best compromise between efficacy and tolerability in most patients. In some women with very inflammatory or resistant acne, the dose may be increased to 150 or even 200 mg per day, but only under medical supervision.

Is there a dose effect?

Yes. Studies show a dose-response relationship: the higher the dose, the greater the potential efficacy. However, side effects also increase, notably menstrual irregularities and breast tenderness. This is why current recommendations favour a gradual, individualised approach rather than a high dose from the outset.

Can it be combined with other treatments?

Yes. It is in fact one of the most effective strategies. Spironolactone can be combined with:

• a topical retinoid;
• benzoyl peroxide;
• azelaic acid;
• certain hormonal contraceptives;
• exceptionally with isotretinoin, in specific situations assessed by the doctor.

These combinations often achieve faster improvement while limiting the dose of each treatment.

Tolerability: should you worry about side effects?

The good tolerability of spironolactone is one of its main strengths. Clinical trials show that most side effects are mild, reversible and dose-dependent. The most frequently reported are:

• menstrual irregularities;
• breast tenderness or pain;
• increased frequency of urination;
• a feeling of dizziness at the start of treatment;
• moderate fatigue;
• headaches.

In most cases, these symptoms subside spontaneously after a few weeks or can be limited by adjusting the dose.

Is the risk of hyperkalaemia overestimated?

This is probably one of the most important messages of the new publications. In young, healthy women with no kidney disease or associated potassium-raising treatment, the risk of hyperkalaemia is extremely low.

Several large recent studies suggest that routine potassium testing is no longer essential in these low-risk patients. However, blood monitoring remains recommended in:

• patients over 45;
• people with kidney failure;
• people taking ACE inhibitors, ARBs or other potassium-raising medicines;
• patients with cardiovascular disease.

Pregnancy, breastfeeding and fertility: what precautions are essential?

The question of pregnancy is probably the most important point about spironolactone. Because of its antiandrogen activity, this molecule is contraindicated during pregnancy. Animal data show a risk of feminisation of the male foetus when exposure occurs during the first weeks of embryonic development. In humans, data remain limited and relatively reassuring, but insufficient to challenge this contraindication.

As a precaution, learned societies therefore recommend avoiding any exposure during pregnancy.

Is contraception necessary?

Yes. Any woman of childbearing age treated with spironolactone should have effective contraception throughout the treatment. In practice, many patients use a contraceptive pill, which has a double benefit: preventing pregnancy and improving the menstrual irregularities sometimes induced by spironolactone. This combination is now widely used in clinical practice.

Can treatment be continued during breastfeeding?

Unlike pregnancy, data on breastfeeding are rather reassuring. Available studies show that the amounts of spironolactone and its main metabolite found in breast milk are very low. No particular toxicity has been demonstrated in infants exposed through breastfeeding. Current recommendations therefore consider that spironolactone may be considered in certain situations, after an individual benefit/risk assessment.

Breast cancer, long-term safety and current place

For many years, concern persisted about a possible increased risk of breast cancer in women treated with spironolactone. This fear came mainly from old studies carried out in rats with extremely high doses, far from those used in humans.

Since then, several large cohort studies and several meta-analyses have largely reassured the scientific community.

The data are now reassuring

The most recent publications show no significant increase in the risk of:

• breast cancer;
• ovarian cancer;
• endometrial cancer;
• recurrence of a treated breast cancer.

These results have profoundly changed the perception of spironolactone, now regarded as a safe treatment when prescribed in correctly selected patients.

What is its current place in international guidelines?

Recent recommendations from the American Academy of Dermatology and the syntheses published in JAAD Reviews now position spironolactone among the reference systemic treatments in women with:

• acne persisting after adolescence;
• hormonal acne;
• acne recurring after a course of isotretinoin;
• acne requiring several successive antibiotic treatments.

The current goal is clear: to limit the prolonged use of antibiotics when effective alternatives exist. For a broader view of management, see our complete guide to hormonal acne.

In summary

Spironolactone is now establishing itself as one of the most valuable treatments for hormonal acne in adult women. Recent publications, in particular the JAAD Reviews systematic review (2025), confirm its efficacy, good tolerability and value within a strategy to limit the prolonged use of antibiotics.

Like any systemic treatment, it requires a personalised prescription, an assessment of contraindications and appropriate follow-up. In correctly selected patients, it now represents a first-rate therapeutic option, supported by a high level of evidence.

The Clínica Valorian analysis

The evolution of scientific knowledge shows a genuine paradigm shift in the management of female acne. Spironolactone is no longer seen as a mere alternative to classic treatments, but as a background treatment targeting one of the essential mechanisms of hormonal acne.

In our practice, it finds its place particularly in women with persistent, recurrent acne or acne associated with signs of hyperandrogenism, after a full medical assessment. The aim is to offer an effective, lasting and individualised treatment while limiting unnecessary exposure to antibiotics.